Thursday - March 12, 2026

Category Archives: Services

Autistic Disorder Pipeline Expands with 25+ Companies and 25+ Therapies in Development Across Clinical Stages, Reveals DelveInsight

Autistic Disorder Pipeline Key Autistic Disorder companies include AbbVie, Yamo Pharmaceuticals, Stalicla SA, Vanda Pharmaceuticals, Paxmedica, SciSparc, Scioto Biosciences, Hoffmann-La Roche, ACADIA Pharmaceuticals Inc., Neurotech International, Neuren Pharmaceuticals, MapLight Therapeutics, Jazz Pharmaceuticals, Axial Therapeutics Inc., and several others. DelveInsight’s “Autistic … Continue reading →

Atopic Dermatitis Pipeline Expands with 120+ Therapies and 100+ Companies Advancing Novel Treatments, Reveals DelveInsight Report

Atopic Dermatitis Pipeline Atopic Dermatitis companies including Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, and Arcutis Biotherapeutics, among others are actively developing treatment options for atopic dermatitis. The “Atopic Dermatitis Pipeline Insight, 2026” report by DelveInsight presents … Continue reading →

Autosomal Dominant Polycystic Kidney Disease Market Set for Robust Growth by 2034 Amid Advancing Therapeutics Landscape | DelveInsight

The dynamics of the autosomal dominant polycystic kidney disease market are anticipated to change in the coming years, owing to the launch of emerging therapies such as XRx-008 (Xortx Therapeutics), CYX082 (Novartis), AZD1613 (AstraZeneca), VX-407 (Vertex Pharmaceuticals), ABBV-CLS-628 (Calico Life … Continue reading →

Chronic Lymphocytic Leukemia Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2026” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline landscape. It covers the Chronic Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Cholangiocarcinoma Clinical Trial Pipeline Shows Potential with Active Contributions from 55+ Key Companies | DelveInsight

DelveInsight’s, “Cholangiocarcinoma Pipeline Insight 2026” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics … Continue reading →

Advanced Renal Cell Carcinoma Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Advanced Renal Cell Carcinoma Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the Advanced Renal Cell Carcinoma Pipeline drug profiles, including clinical and nonclinical … Continue reading →

Brain Metastases Clinical Trial Pipeline Expands as 40+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Brain Metastases Pipeline Insights 2026” report provides comprehensive insights about 40+ Brain Metastases companies and 45+ pipeline drugs in Brain Metastases pipeline landscape. It covers the Brain Metastases pipeline drug profiles, including clinical and nonclinical stage products. Brain Metastases … Continue reading →

Dividend Data Launches “Dividend Data for Spreadsheets,” Bringing 30+ Years of Dividend and Financial Data Directly to Excel and Google Sheets

The new spreadsheet add-in eliminates manual copy-paste research for investors and analysts, offering 16 formulas, 80,000+ supported tickers, and a permanent free tier. Dividend Data has officially announced the launch of Dividend Data for Spreadsheets, a free financial data add-in … Continue reading →